Meet the Start-ups

Nazma Ilahibaks

Nazma Ilahibaks | CEO & Co-founder | JAMA Therapeutics

Dr. Nazma Ilahibaks is the CEO and co-founder of JAMA Therapeutics (JAMA Tx), a preclinical stage cardiac gene therapy spin-off from University Medical Center Utrecht in the Netherlands. JAMA Tx is tackling one of the hardest problems in genetic medicine for heart patients: delivery. 

With over nine years of experience in non-viral drug delivery for cardiovascular applications, she is a co-inventor of the deVINCI delivery platform. Prior to founding JAMA Tx, she held business development roles at the Netherlands’ largest cardiovascular center, where she drove international public-private partnerships with pharma and medtech, and later at the country’s leading regenerative medicine ecosystem organization, supporting academic venture creation. 

Nazma holds a PhD in Regenerative Medicine from Utrecht University and an MSc in Drug Innovation, from which she graduated with the distinctions of honors and cum laude.



About JAMA Therapeutics

JAMA Therapeutics (JAMA Tx) is a preclinical-stage cardiac gene therapy spin-off from the Experimental Cardiology lab at University Medical Center Utrecht in the Netherlands. Inherited cardiomyopathies affect roughly 1 in 200 to 500 people, yet care is still largely limited to symptom management or heart transplantation because disease-modifying cardiac gene therapy remains constrained by the safety and efficacy limits of today’s delivery vehicles in reaching the heart. JAMA Tx is developing two proprietary cell-derived nanoparticle delivery platforms designed to transport RNA, proteins, and programmable gene editors into hard-to-reach cells. 

Our approach combines biology-first targeting, endogenous cargo loading, and a platform strategy supporting multiple therapeutic programs. Through our proprietary delivery platform, we are advancing two cardiac gene therapy programs aimed at enabling durable, disease modifying treatments for patients suffering from life-threatening inherited heart disease.

Powered by:
Hyphen Projects   

    Connect     

Join Global Investor Forum
Privacy Policy
Terms & Conditions 
Chamber of Commerce: 32110979
VAT no: NL8184.34.491.B01		         
 
 

                                     
         
   REGISTER NOW
    SUBSCRIBE TO OUR NEWSLETTER
 
© Copyright 2025 by Hyphen Projects